open access publication

Article, 2024

Core Legal Challenges for Medical 3D Printing in the EU

Healthcare Switzerland, ISSN 2227-9032, Volume 12, 11, 10.3390/healthcare12111114

Contributors

Pettersson A.B.V. 0000-0003-3262-2990 (Corresponding author) [1] Ballardini R.M. 0000-0002-7662-9281 [2] Mimler M. 0000-0002-9457-2506 [3] Li P. 0000-0001-9171-1729 [4] Salmi M. 0000-0002-7295-3551 [5] Minssen T. 0000-0002-3286-4888 [6] Gibson I. 0000-0002-4149-9122 [7] Makitie A. 0000-0002-0451-2404 (Corresponding author) [1] [8]

Affiliations

  1. [1] University of Helsinki
  2. [NORA names: Finland; Europe, EU; Nordic; OECD];
  3. [2] University of Lapland
  4. [NORA names: Finland; Europe, EU; Nordic; OECD];
  5. [3] City University London
  6. [NORA names: United Kingdom; Europe, Non-EU; OECD];
  7. [4] University of Sussex
  8. [NORA names: United Kingdom; Europe, Non-EU; OECD];
  9. [5] Aalto University
  10. [NORA names: Finland; Europe, EU; Nordic; OECD];

Abstract

3D printing has been adopted into routine use for certain medical applications, but more widespread usage has been hindered by, among other things, unclear legislation. We performed an analysis, using legal doctrinal study and legal informatics, of relevant EU legislation and case law in four issues relevant to medical 3D printing (excluding bioprinting or pharmacoprinting): pre-market approval, post-market liability, intellectual property rights, and data protection. Several gaps and uncertainties in the current legislation and interpretations were identified. In particular, we regard the current EU regulatory framework to be quite limiting and inflexible, exemplifying a cautionary approach common in EU law. Though the need to establish high safety standards in order to protect patients as a disadvantaged population is understood, both legal uncertainties and overregulation are seen as harmful to innovation. Hence, more adaptive legislation is called for to ensure continuous innovation efforts and enhanced patient outcomes.

Keywords

3D printing, additive manufacturing, legal issues, legislation, medical, medicine, regulation

Funders

  • Emil Aaltosen Säätiö
  • South-Karelia Medical Association
  • Suomen Lääketieteen Säätiö
  • Novo Nordisk Fonden
  • Strategic Research Council
  • UK Research and Innovation
  • Economic and Social Research Council
  • International Collaborative Bioscience Innovation and Law Programme
  • Suomen Akatemia
  • Viipuri Tuberculosis Foundation

Data Provider: Elsevier